454. Deputy Ken O'Flynn asked the Minister for Health the average time taken by the National Centre for Pharmacoeconomics and her Department to complete health technology assessments and reimbursement decisions on oncology drugs in the past three years; and whether target timelines exist to expedite access for public patients. [52825/25]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn under the heading Cancer Services.
15 questions match, newest first.
455. Deputy Ken O'Flynn asked the Minister for Health if her Department has entered into outcomes-based or risk-sharing agreements with pharmaceutical companies in respect of new cancer drugs; and if so, to provide details of the drugs concerned, the duration of the agreements, and the outcomes being measured. [52826/25]
456. Deputy Ken O'Flynn asked the Minister for Health the projected level of additional annual funding required over the next five years to ensure that all newly approved cancer drugs are made available to public patients in a timely manner; and whether ring-fenced oncology funding is being considered within her Department. [52827/25]
457. Deputy Ken O'Flynn asked the Minister for Health whether her Department has carried out any equality or impact assessment on disparities in access to oncology drugs between public and private patients; and if so, to publish those findings. [52828/25]
458. Deputy Ken O'Flynn asked the Minister for Health to provide comparative data on the time from European Medicines Agency approval to reimbursement for new oncology medicines in Ireland versus other EU member states; and to indicate whether Ireland is above or below the EU average. [52829/25]
459. Deputy Ken O'Flynn asked the Minister for Health if she will publish in full the rationale, minutes, and assessments underpinning reimbursement decisions on oncology drugs since 2020; and if not, the reason for the continued confidentiality. [52830/25]
460. Deputy Ken O'Flynn asked the Minister for Health whether a national registry of oncology patients treated with newer cancer therapies is maintained; and if so, to outline how this real-world data informs reimbursement and future access decisions. [52831/25]
461. Deputy Ken O'Flynn asked the Minister for Health the steps being taken to accelerate the availability of oncology generics and biosimilars to reduce cost barriers for the public health system; and whether legislative or regulatory reform is being considered in this regard. [52832/25]
2493. Deputy Ken O'Flynn asked the Minister for Health if she has considered introducing a structured screening programme for prostate cancer, similar to BreastCheck and CervicalCheck, given international evidence and recent high-profile cases highlighting the consequences of late diagnoses. [46373/25]
2494. Deputy Ken O'Flynn asked the Minister for Health the public information campaigns that are in place to encourage men over 50, or those in high-risk categories, to request PSA testing from their GP; and if she will consider funding a targeted awareness initiative. [46374/25]
2495. Deputy Ken O'Flynn asked the Minister for Health the number and percentage of prostate cancer cases diagnosed at stage three or four in each of the past five years; and the steps being taken to improve earlier detection rates. [46375/25]
2496. Deputy Ken O'Flynn asked the Minister for Health if her Department will review whether men without regular GP access are at a disadvantage in accessing PSA testing; and if alternative access pathways will be considered. [46376/25]
2497. Deputy Ken O'Flynn asked the Minister for Health if her Department has conducted a cost–benefit analysis of introducing routine PSA screening for men in certain age brackets, in terms of both survival outcomes and reduced treatment costs for late-stage cancer. [46377/25]
368. Deputy Ken O'Flynn asked the Minister for Health if she will consider approving coverage for a type of treatment (details supplied) as a matter of urgency, given the potentially life-saving impact; whether she intends to provide funding for vyloy through the HSE, or under the medical card scheme, for cases where it is clinically indicated; and if she will make a statement on the matter. [27783/25]
2022. Deputy Ken O'Flynn asked the Minister for Health if she plans to reduce the age eligibility for the BreastCheck screening programme from 50 to 40 years-of-age, given that earlier screening could lead to earlier detection of breast cancer and improved outcomes for patients; and if she will make a statement on the matter. [18804/25]